Below are the most recent publications written about "Ki-67 Antigen" by people in Profiles.
-
Yarman Y, Post R, Breslin Z, Solomides CC, Gargano SM. Utility of Proliferation Markers Ki-67 and PHH3 in Predicting Malignancy in Basaloid Salivary Gland Neoplasms: A Study Using Digital Image Analysis of Cytology Cell Blocks. Diagn Cytopathol. 2025 May; 53(5):238-245.
-
Hrizat AS, Doxzon KA, O'Neill R, Post RP, Brachtel EF. Evaluation of HER2-Low breast carcinoma in metastatic settings: a cytological approach to proliferation and survival. J Am Soc Cytopathol. 2025 May-Jun; 14(3):182-190.
-
Lee YW, Ahn SH, Lee YJ, Yoo TK, Kim J, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Lee SB. Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer. PLoS One. 2023; 18(8):e0290174.
-
Lee J, Lee YJ, Bae SJ, Baek SH, Kook Y, Cha YJ, Lee JW, Son BH, Ahn SH, Lee HJ, Gong G, Jeong J, Lee SB, Ahn SG. Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer. JAMA Netw Open. 2023 08 01; 6(8):e2330961.
-
Yi M, Zhan T, Peck AR, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Sun Y, Rui H, Chervoneva I. Selection of optimal quantile protein biomarkers based on cell-level immunohistochemistry data. BMC Bioinformatics. 2023 Jul 22; 24(1):298.
-
Khanna O, Fathi Kazerooni A, Arif S, Mahtabfar A, Momin AA, Andrews CE, Hafazalla K, Baldassari MP, Velagapudi L, Garcia JA, Sako C, Farrell CJ, Evans JJ, Judy KD, Andrews DW, Flanders AE, Shi W, Davatzikos C. Radiomic signatures of meningiomas using the Ki-67 proliferation index as a prognostic marker of clinical outcomes. Neurosurg Focus. 2023 06; 54(6):E17.
-
Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel E, Pirrie S, Schnabel CA, Rea D, Bartlett JMS. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Res. 2022 12 16; 24(1):90.
-
Dowsett M, Nielsen TO, Rimm DL, Hayes DF. Ki67 as a Companion Diagnostic: Good or Bad News? J Clin Oncol. 2022 11 20; 40(33):3796-3799.
-
Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, L?nkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Mod Pathol. 2022 10; 35(10):1362-1369.
-
Ferguson CJ, Urso O, Bodrug T, Gassaway BM, Watson ER, Prabu JR, Lara-Gonzalez P, Martinez-Chacin RC, Wu DY, Brigatti KW, Puffenberger EG, Taylor CM, Haas-Givler B, Jinks RN, Strauss KA, Desai A, Gabel HW, Gygi SP, Schulman BA, Brown NG, Bonni A. APC7 mediates ubiquitin signaling in constitutive heterochromatin in the developing mammalian brain. Mol Cell. 2022 01 06; 82(1):90-105.e13.